期刊
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
卷 51, 期 4, 页码 1107-1110出版社
SPRINGER
DOI: 10.1007/s11239-020-02105-8
关键词
Coronavirus disease 2019; Severe pneumonia; Coagulopathy; D-dimer
资金
- National Mega Project on Major infectious Disease Prevention of China [2017ZX10103005-007]
This study compared coagulation features and clinical outcomes of patients with severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. The 28-day mortality rate was higher in the COVID group, which had older patients with higher platelet counts. Patients with markedly elevated D-dimer in the COVID group may benefit from anticoagulant treatment.
Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 +/- 12.0 vs. 58.4 +/- 18.0, years, P < 0.001) and with higher platelet count (215 +/- 100 vs. 188 +/- 98, x10(9)/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 mu g/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据